IBIO - iBio, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

iBio, Inc.

600 Madison Avenue
Suite 1601
New York, NY 10022
United States

Full Time Employees54

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert B. KayExec. Chairman & CEO314.9kN/A1940
Mr. Robert L. ErwinPres251.67kN/A1953
Mr. James P. Mullaney CPA, CPAChief Financial Officer240kN/A1971
Mr. Terence E. RyanChief Scientific Officer200kN/A1955
Dr. Renato LoboChief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.

Corporate Governance

iBio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.